

Invitation to presentation of Xbrane Biopharma's interim report January – June 2022 on July 22, 2022

Xbrane Biopharma AB invites to a teleconference for investors, analysts and media on Friday, July 22th, 2022, at 10.00 a.m. CET. Xbrane will publish the company's interim report January – June 2022, on Friday, July 22, 2022, at 8.00 a.m. CET.

Martin Åmark, CEO, and Anette Lindqvist, CFO/IR, will present the interim report January – June 2022, followed by a Q&A session. The presentation will be in English. To attend, please follow the link below:

[Presentation of interim report January - June 2022](#)

Contacts

Martin Åmark, CEO
M: +46 76 309 37 77
E: martin.amark@xbrane.com

Anette Lindqvist, CFO/IR
M: +46 76 325 60 90
E: anette.lindqvist@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting SEK 332 billion in annual sales of the respective reference products, with the leading one under registration in Europe. Xbrane's head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

Attachments

[Invitation to presentation of Xbrane Biopharma's interim report January – June 2022 on July 22, 2022](#)